SBC Medical Expands Franchise Network and Customer Loyalty Amid Strategic Restructuring
SBC Medical Group Holdings Inc. is executing a strategic shift to enhance its leadership in the cosmetic surgery market through franchise growth, increased repeat visits, and international expansion despite short-term revenue declines.
SBC Medical Group Holdings Inc. (NASDAQ: SBC), a Japanese cosmetic surgery clinic chain, advanced its strategic restructuring in the first half of 2025 by expanding franchise locations and boosting customer loyalty metrics. The company reported 259 franchise locations as of June 30, 2025, a 16% year-over-year increase, alongside 6.31 million visits over the past twelve months. Repeat customer visits grew 14%, and unique visits rose 10%, underscoring the brand's resilience amid declining discretionary spending in Japan.
Chairman and CEO Yoshiyuki Aikawa emphasized that the revenue decline—16% year-over-year to $91 million for H1 2025 and 18% to $43 million in Q2—was anticipated due to restructuring efforts. The company discontinued its staffing business, executed targeted divestitures, and revised its fee structure to streamline operations and focus on higher-margin models. Aikawa stated, "We are executing our strategic plan with precision, demonstrating a scale that is unmatched in Japan."
SBC Medical's strategy includes making aesthetic medicine more accessible while differentiating through advanced treatments and competitive pricing. The company is expanding into the U.S. and Singapore to capture growth opportunities. The repeat rate among existing customers reached 72% in Q2, with average revenue per visit at $279, up 13% year-over-year, highlighting operational efficiency and brand strength.
Key initiatives progressed with the acquisition of MB Career Lounge Co. Ltd., a provider of management support services for medical institutions, to enhance consulting and training capabilities. Plans to integrate JUN CLINIC, a network with high customer spending, aim to bolster SBC Medical's premium offerings. The company ended Q2 with $153 million in cash, providing flexibility for future investments.
Reflecting management's confidence, SBC Medical completed a $5 million share buyback program on July 22, citing undervaluation of its stock and growth potential. Inclusion in the Russell 3000® Index in June may increase investor visibility and recognition of its market position. Despite near-term challenges, the company's focus on franchise optimization and international expansion positions it for long-term competitiveness in the growing aesthetic medicine sector.